Coversure adds medical cannabis broker as UK prescriptions climb
The UK broker network's move, reported Nov. 2, treats private cannabis prescribing as its own insurance category as clinic and pharmacy volumes grow.

Illuminated neon pharmacy sign with prescriptions on a storefront at night.
Coversure adds a medical cannabis specialist to its UK network
Coversure, a UK insurance broker network, brought a medical cannabis broker into its fold on Nov. 2, according to Insurance Business.
The trade outlet framed the addition against a surge in UK prescriptions. That framing is the story. Brokers don't build specialist capacity for markets they expect to shrink.
It's a small corporate move with a large implication: someone in UK insurance has decided medical cannabis is no longer a niche to be declined at the front door.
What the Insurance Business report doesn't tell us
The public signal doesn't name the broker, the insurers behind any product, premium levels, or the size of the prescription increase.
CannIntel isn't filling those gaps with guesses. We haven't seen deal terms, and we haven't independently verified the prescription figures behind the headline.
Not yet. Until the parties publish details, treat the move as a directional indicator, not a market-sizing event.
Why prescribing growth creates an insurance problem
The UK legalised specialist prescribing of cannabis-based products for medicinal use on Nov. 1, 2018, and most patients since have gone through private clinics rather than the NHS.
That structure matters for risk. Private clinics are regulated by the Care Quality Commission (CQC), prescribers must be on the General Medical Council's specialist register, and the products are controlled drugs under the Misuse of Drugs Regulations. Each layer carries its own liability. A standard commercial package may not price any of it correctly.
More prescriptions mean more patient contact, more dispensing and more imported stock moving through licensed channels overseen by the Home Office and MHRA. Exposure scales with volume. A broker who understands that, and can place it, is worth having.
Where the underwriting exposure sits
Four exposure points do the heavy lifting for any UK medical cannabis risk, and generalist brokers often misread at least one of them.
- Clinical negligence and professional indemnity for prescribers and clinic operators
- Product liability for importers, distributors and dispensing pharmacies
- Stock, storage and transit cover for controlled, temperature-sensitive goods
- Patient-side questions, including how life, travel and motor insurers treat a disclosed prescription
These categories are our read of where specialist knowledge matters. They aren't drawn from the Coversure announcement. The last item is the least settled. Patients feel it directly.
How the UK compares with Germany and Canada
The UK runs a prescription-led medical model closer to Germany's than to Canada's, but with far thinner public reimbursement.
Germany's BfArM oversees the national cannabis agency and import controls, and since April 2024 medical cannabis has sat under its own law rather than the Narcotics Act. Health Canada, by contrast, licenses producers directly under the Cannabis Act and runs a patient access framework alongside adult-use sales.
The UK sits in a different spot. Supply leans heavily on imports, and payment is largely out of pocket. That puts commercial risk on clinics and pharmacies, which is precisely where a specialist broker earns a fee.
What operators and investors should take from it
Specialist broker capacity lowers a hidden cost for UK clinics and importers: the time spent finding a carrier willing to read the risk.
In a market where product, prescriber and patient all carry separate liability, the scarce asset isn't capital. It's a carrier that understands the file.
Operators should ask any broker which insurers actually back its cannabis placements, and whether cover survives a regulator inspection finding. Investors should watch whether other broker networks follow. That math is hard to ignore: if one network moves, competitors rarely sit still.
For wider context on supply, licensing and prescriber trends, see the CannIntel topic hub on the UK medical cannabis market.
What to watch next
The next evidence will be the details: carrier names, product scope and any published prescription data behind the surge.
Watch for Coversure or the new broker to disclose which risks they will place, and for UK clinic groups to cite insurance terms in their own filings. Any move by the CQC or MHRA that raises compliance expectations would push demand for specialist cover higher, so those two regulators are the variable to track.
Frequently asked questions
What did Coversure announce about medical cannabis?
According to Insurance Business, Coversure added a medical cannabis broker to its UK network on Nov. 2, 2026, as prescriptions rise. The report as summarised does not name the broker or give terms, and CannIntel has not independently confirmed further details.
Since when has medical cannabis been prescribable in the UK?
UK specialist doctors have been able to prescribe cannabis-based products for medicinal use since Nov. 1, 2018. Most prescribing since then has occurred through private clinics rather than the NHS.
Who regulates UK medical cannabis clinics?
Private clinics are regulated by the Care Quality Commission (CQC), prescribers must sit on the General Medical Council's specialist register, and the Home Office and MHRA oversee controlled-drug licensing and medicines standards.
Why does medical cannabis need specialist insurance?
Clinics, importers and pharmacies face clinical, product and storage risks tied to controlled drugs. Generalist policies may not price or cover them correctly, which is where specialist brokers add value. This is CannIntel's analysis, not a Coversure statement.
Sources
The cannabis newsletter you forward to your team.
Federal policy, market data, grower alerts, and the one story that matters today. Sent every weekday at 7am. Free.
No spam. Unsubscribe with one click. 21+ only.
Related from Business

Vireo Growth Completes Acquisition of FLUENT Corp.
Minneapolis-based Vireo has closed its all-share purchase of Tampa's FLUENT, folding one of Florida's larger vertically integrated operators into its multistate platform.

Charlotte's Web Q3: CBD Sales Fall as Operating Loss Narrows
Charlotte's Web reported lower third-quarter CBD revenue but a smaller operating loss, a split result that leaves the hemp pioneer's path to profitability unresolved.

Hemp insurers face coverage gaps ahead of Dec. 11 deadline
Insurance Business reported coverage gaps are emerging for hemp operators as the December 11 federal deadline approaches, leaving policy language and tax treatment unsettled.
More from the newsroom

Pennsylvania Op-Ed Presses Lawmakers on Small-Business Access in Legalization
A published opinion piece argues any Pennsylvania adult-use law should open licensing to smaller operators, not just the incumbent medical cannabis companies. No bill has moved.

Oklahoma Police Offer NC Cautionary Lessons on Cannabis Legalization
NC Newsline reports Oklahoma law enforcement is warning North Carolina lawmakers about enforcement and licensing gaps as the state weighs cannabis legalization recommendations.

Illinois Hemp Limit Takes Effect as Three States Move on Rules
Illinois' hemp limit is live, while Massachusetts, Washington and California each advanced separate operator-facing changes covering testing, co-ops and transfers.